ClinicalTrials.gg
RecruitingNCT07119983Updated Sep 15, 2026

Effect of Stress Ball Applied During Surgical Debridement/Dressing on Pain, Distress, and Physiological Parameters in Patients With Diabetic Foot Ulcers

An interventional study of Stress ball in Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus, sponsored by Cukurova University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Cukurova University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Diabetes mellitus (DM) is a common metabolic disease characterized by hyperglycemia, resulting from a deficiency or insufficiency of insulin. Diabetic foot ulcers (DFU), a late complication of diabetes, develop as a result of peripheral neuropathy, peripheral arterial disease, and trauma, negatively impacting individuals' quality of life and increasing the rate of hospitalization and amputation. While sharp debridement, one of the most effective methods in the management of diabetic foot ulcers, accelerates healing, it often causes pain and anxiety, which negatively impacts the treatment process. The physiological effects of anxiety include increased respiratory and heart rates, increased blood pressure, and prolonged procedure times. These effects can reduce patient compliance and complicate nursing care.

Non-pharmacological interventions offer important alternatives for pain and anxiety management. One such method, the use of a stress ball, is based on a distraction technique and is used to reduce individuals' emotional and physiological stress levels. The literature has demonstrated the positive effects of stress balls during endoscopy, biopsy, and skin procedures. However, there is insufficient evidence regarding the use of stress balls during sharp debridement. Therefore, this study aimed to evaluate the effects of stress balls on pain, distress, and physiological parameters during surgical debridement in patients with diabetic foot ulcers. The results of this study are expected to contribute to nursing care.

02

Conditions studied

  • Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus

Keywords

  • Diabetic foot ulcer
  • sharp debridement
  • pain
  • anxiety
  • stress ball
  • nursing care
03

In context

Diabetic Foot

1,077 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's planned enrollment of 84 is above the median of 60 across 847 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Cukurova University is the lead sponsor of 259 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who agree to participate in the study and sign the
  • Form will be included in the study.
  • They are over 18 years of age,
  • They are literate in Turkish,
  • They are undergoing surgical debridement for the first time,
  • They are receiving inpatient treatment in the ward, and
  • They have pain ≥1 on the Visual Analog Scale (VAS) before the procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients who have a diagnosed psychiatric or mental illness,
  • Regular painkiller use and chronic pain,
  • Visual, hearing, perception, or communication problems,
  • Physically impaired (such as an open wound on the hand or lack of muscle strength to squeeze a stress ball),
  • Decided to undergo an intervention to reduce pain before debridement (such as local anesthesia, nerve blockade, opioid analgesics, etc.),
  • Used non-pharmacological methods to reduce pain before the procedure will not be included in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Stress ball

    The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.

    Behavioral: Stress ball

  • No intervention
    Control Group

    Routine care

Interventions

  • BehavioralStress ball

    The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.

06

What researchers measure

Primary outcomes

  1. Pain assessment

    Visual Analogue Scale -VAS: The scale was developed by Price and colleagues in 1983 for use in assessing subjectively perceived pain. Eti-Aslan noted in his study that the VAS is more sensitive and better defined in assessing acute pain. It is a 10 cm (100 mm) ruler with the word "painlessness" written on one end and "the most severe pain" written on the other. Participants were asked to indicate the intensity of pain they were currently experiencing, explaining that "0" on the scale means "I feel no pain" and that increasing numbers indicate increased pain intensity. "10" means "I feel the most severe pain." A higher score on the scale indicates increased pain.

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

  2. Anxiety Assesment (The Distress Thermometer)

    The Distress Thermometer was first developed by Roth and colleagues for use in identifying non-pathological distress in patients undergoing cancer treatment after answering the necessary questions. The distress level is rated from 0 to 10. The practitioner expresses the distress experienced using the numbers on the thermometer. A score of zero indicates no distress, while a score of 10 indicates the highest level of distress. The green zone encompasses scores from 0 to 3. Individuals experiencing distress within this range are capable of managing their distress. The yellow zone encompasses scores from 4 to 6. A distress score in this range indicates that the individual is unable to manage their distress and requires intervention to return them to the green zone. The red zone encompasses scores from 7 to 10. Individuals experiencing distress within this range require urgent and comprehensive intervention.

    Time frame: Before the Procedure and baseline, after an average of 20-30 minutes

  3. Physiological Parameters (heart rate, systolic and diastolic blood pressure, oxygen saturation and respiratory rate)

    Heart rate, systolic and diastolic blood pressure, oxygen saturation, and respiratory rate will be recorded before, during, and after debridement. Systolic and diastolic blood pressure will be measured for patients in the study and control groups using the ERKA adult aneroid blood pressure monitor, while oxygen saturation and heart rate will be measured using the Masimo SET® Pulse Oximetry. Both devices will be calibrated before data collection.

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

  4. Physiological Parameter: heart rate

    Heart rate will be measured using the Masimo SET® Pulse Oximetry. Devices will be calibrated before data collection.

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

  5. Physiological Parameters: systolic and diastolic blood pressure

    Systolic and diastolic blood pressure will be measured for patients in the study and control groups using the ERKA adult aneroid blood pressure monitor

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

  6. Physiological Parameter: oxygen saturation

    Oxygen saturation will be measured using the Masimo SET® Pulse Oximetry. Device will be calibrated before data collection.

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

  7. Physiological Parameter: respiratory rate

    Respiratory rate will be monitored for one minute, with each inspiration and expiration counted as a breath.

    Time frame: Before the Procedure, during the Procedure (10th minute), and baseline, after an average of 20-30 minutes

Other outcomes

  1. Meggitt-Wagner classification

    Meggitt-Wagner Classification of Diabetic Foot: The Meggitt-Wagner classification was developed by Meggitt in 1976 and revised by Wagner in 1981. This classification system, which grades the wound into six categories from stage 0 to stage 5 based on the depth of the wound and the presence of osteomyelitis and gangrene, is evaluated based on observational findings, excluding ulcer depth. Findings of ischemia and infection are limited and do not include the presence of neuropathy. However, evaluation of these factors is known to have a positive impact on the healing process of diabetic foot ulcers.

    Time frame: in recruitment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Purcell A, Buckley T, King J, Moyle W, Marshall AP. Topical Analgesic and Local Anesthetic Agents for Pain Associated with Chronic Leg Ulcers: A Systematic Review. Adv Skin Wound Care. 2020 May;33(5):240-251. doi: 10.1097/01.ASW.0000658572.14692.fb. PubMed 32304447 ↗
  • Hajimohammadi K, Parizad N, Bagheri M, Faraji N, Goli R. Maggot therapy, alginate dressing, and surgical sharp debridement: Unique path to save unresponsive diabetic foot ulcer. Int J Surg Case Rep. 2023 Oct;111:108907. doi: 10.1016/j.ijscr.2023.108907. Epub 2023 Oct 4. PubMed 37804682 ↗
  • Shamloul G, Khachemoune A. Reappraisal and updated review of maggot debridement therapy in chronic lower extremity ulcers. Int J Dermatol. 2023 Jul;62(7):962-968. doi: 10.1111/ijd.16619. Epub 2023 Mar 7. PubMed 36880424 ↗
  • McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023 Jan 1;46(1):209-221. doi: 10.2337/dci22-0043. PubMed 36548709 ↗
  • Jia H, Wang X, Cheng J. Knowledge, Attitudes, and Practices Associated With Diabetic Foot Prevention Among Rural Adults With Diabetes in North China. Front Public Health. 2022 May 20;10:876105. doi: 10.3389/fpubh.2022.876105. eCollection 2022. PubMed 35669753 ↗
  • Alshammari L, O'Halloran P, McSorley O, Doherty J, Noble H. The effectiveness of foot care educational interventions for people living with diabetes mellitus: An umbrella review. J Tissue Viability. 2023 Aug;32(3):406-416. doi: 10.1016/j.jtv.2023.06.001. Epub 2023 Jun 16. PubMed 37369610 ↗
  • van Netten JJ, Raspovic A, Lavery LA, Monteiro-Soares M, Paton J, Rasmussen A, Sacco ICN, Bus SA. Prevention of foot ulcers in persons with diabetes at risk of ulceration: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2024 Mar;40(3):e3652. doi: 10.1002/dmrr.3652. Epub 2023 May 27. PubMed 37243880 ↗
  • Aslan F, Tosun B, Altinok Ersoy N, Ozen N. The effect of a stress ball on pain and anxiety during sharp debridement in patients with diabetic foot ulcers: A randomized controlled, single-blind study. J Tissue Viability. 2025 May;34(2):100861. doi: 10.1016/j.jtv.2025.100861. Epub 2025 Jan 26. PubMed 39892227 ↗
  • Najafi B, Mishra R. Harnessing Digital Health Technologies to Remotely Manage Diabetic Foot Syndrome: A Narrative Review. Medicina (Kaunas). 2021 Apr 14;57(4):377. doi: 10.3390/medicina57040377. PubMed 33919683 ↗
  • Yang L, Rong GC, Wu QN. Diabetic foot ulcer: Challenges and future. World J Diabetes. 2022 Dec 15;13(12):1014-1034. doi: 10.4239/wjd.v13.i12.1014. PubMed 36578870 ↗

Individual participant data

Plan to share: Yes — Results regarding the effects of stress ball use on pain, anxiety, and hemodynamic parameters surgical debridement in individuals with diabetic foot ulcers will be shared. However, your personal information will not be shared.

Supporting information: Clinical study report

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

Of 240 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 14 months is below that.

Counting every sponsor, half of 343 studies reached it within 22 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 13, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07119983
Responsible party
Derya Gezer (Assistant Professor, Tarsus University) — Principal investigator
First posted
Aug 13, 2025
Start date
Nov 1, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Derya GEZER, Asisstant Professor
Contact
deryasahhin@hotmail.com
+905076990081
Ezgi Mutluay YAYLA, Asisstant Professor
Contact
ezgiyayla@tarsus.edu.tr
DERYA GEZER, Asisstant Professor
study chair · Tarsus University
EZGİ MUTLUAY YAYLA, Asisstant Professor
study director · Tarsus University
DUDU ALPTEKİN, Dr
study director · CUKUROVA UNİVERSİTY

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion